NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Medline MDLN

Medline listed on Nasdaq on 18 Dec 2025 and is not in the S&P 500. It is worth $49.8 billion. Its price history starts on 19 Dec 2025. Its board has 12 directors, 9 of them independent. 8 other officers are on file. At 30 Jun 2026, Carlyle Group was its largest institutional holder, with 14.2% of the company.

CEO
James M. Boyle
Chair
Charles N. Mills
Listed
18 Dec 2025 on Nasdaq, IPO filings and terms
Headquarters
Northfield, IL
Market cap
$49.8B
19 Nov 2026 close
Revenue
$28.4B
Fiscal year 2025
Price to sales
1.8
Market cap over revenue

Financials

Financial history

Twelve months to 26 Sep 2026, from Medline's quarterly filings.

Quarters since Mar 2025

Revenue
$30.7B
Last four quarters
Net income
$582M
1.9% of revenue
Free cash flow
$1.9B
Operating cash flow less capital spending
P/E
85.5
Market cap over net income

Quarterly results

Each quarter's revenue, net income and free cash flow.

Mar 2025 to Sep 2026

$0$2B$4B$6B$8B20252026$7.9B

Revenue breakdown

Medline's $7.9B of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.

Quarter to Sep 2026

  • Supply Chain Solutions$4.2B, 53.7%
  • Medline Brand$3.6B, 46.3%

Medline's market cap since December 2025

Weekly, up to 13 Nov 2026

Jan 2026MarMayJulSepNov$51.9B

Board and leadership

Board and officers

3 people here also hold roles at other S&P 500 companies.

Board from the proxy filed 23 Apr 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (12)
Charles N. MillsChairNot independent 路 since 1985 路 Risk and ComplianceNon-Executive Former Chief Executive Officer, MedlineChair1985NoRisk and Compliance64
James M. BoyleChief Executive OfficerNot independent 路 since 2023Chief Executive Officer2023No54
Joseph BarattaDirectorIndependent 路 since 2021Global Head of Private Equity, BlackstoneAlso at BlackstoneDirector2021Yes55
Jacob BestDirectorIndependent 路 since 2021 路 Compensation, Nominating and Corporate Governance, Risk and Compliance (chair)Partner, Hellman & FriedmanDirector2021YesCompensation, Nominating and Corporate Governance, Risk and Compliance (chair)41
Todd M. BluedornDirectorIndependent 路 since 2025 路 AuditFormer Chief Executive Officer, Lennox International Inc.Also at Texas InstrumentsOther boards: SamsaraDirector2025YesAudit63
Richard A. GalantiDirectorIndependent 路 since 2025 路 AuditFormer Chief Financial Officer, Costco Wholesale CorporationOther boards: Affirm HoldingsDirector2025YesAudit70
Patrick J. HealyDirectorIndependent 路 since 2025Chief Executive Officer, Hellman & FriedmanDirector2025Yes59
Andrew J. MillsDirectorNot independent 路 since 1985Former President, Medline; Chief Executive Officer and General Partner, Council Ring Capital, LLCDirector1985No65
Robert R. SchmidtDirectorIndependent 路 since 2021 路 Compensation, Nominating and Corporate Governance (chair), Risk and CompliancePartner and Global Co-Head of Healthcare, CarlyleDirector2021YesCompensation, Nominating and Corporate Governance (chair), Risk and Compliance43
Anushka M. SunderDirectorIndependent 路 since 2021 路 Compensation (chair), Nominating and Corporate Governance, Risk and ComplianceSenior Managing Director and Head of Healthcare Private Equity North America, BlackstoneDirector2021YesCompensation (chair), Nominating and Corporate Governance, Risk and Compliance39
Thomas W. SweetDirectorIndependent 路 since 2024 路 Audit (chair), Risk and ComplianceFormer Chief Financial Officer, Dell TechnologiesAlso at 3M and TrimbleDirector2024YesAudit (chair), Risk and Compliance66
Stephen H. WiseDirectorIndependent 路 since 2021Partner and Co-Head of Americas Corporate Private Equity, CarlyleDirector2021Yes53
Officers (8)
Michael B. DrazinChief Financial OfficerLast filed 17 Jun 2026Chief Financial Officer
William J. AbramsExecutive Vice President, Supply Chain SolutionsLast filed 17 Jun 2026Executive Vice President, Supply Chain Solutions
Jessi L. CorcoranPrincipal Accounting OfficerLast filed 9 Jun 2026Principal Accounting Officer
Douglas P. GolwasChief Commercial OfficerLast filed 17 Jun 2026Chief Commercial Officer
Amanda H. LaabsChief Product OfficerLast filed 17 Jun 2026Chief Product Officer
Alexander M. LibermanChief Legal OfficerLast filed 17 Jun 2026Chief Legal Officer
James M. PigottPresidentLast filed 17 Dec 2025President
Christopher P. ShryockChief Human Resources OfficerLast filed 17 Jun 2026Chief Human Resources Officer

Owners and trading

Largest institutional holders

Each fund group's share of Medline. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 29.2% of Medline.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $3.7 million of stock in 1 sale and bought $150 million in 3 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
16 Jun 2026SaleDouglas P. GolwasChief Commercial OfficerChief Commercial OfficerSale100,000$3.7M
5 Jun 2026BuyJessi L. CorcoranPrincipal Accounting OfficerPrincipal Accounting OfficerBuy5,000$171K
18 Dec 2025BuyAndrew J. MillsDirectorDirectorBuy2,586,206$75M
18 Dec 2025BuyCharles N. MillsChairChairBuy2,579,310$75M

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

2 departures and 1 appointment of directors and officers and 1 large insider sale in the last two years.

Left the company or board 2Appointed 1WARN layoff notices 0Large insider sales 1Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Medline's insider sales.

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.